Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | TG6050 |
| Trade Name | |
| Synonyms | TG-6050|TG 6050 |
| Drug Descriptions |
TG6050 is an oncolytic vaccinia virus engineered to express IL-12 and an anti-CTLA4 antibody, which potentially leads to enhanced antitumor immune response and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 694). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| TG6050 | TG6050 | 0 | 1 |